Tesamorelin Before and After: The Week-by-Week Timeline From the Phase 3 Data

Tesamorelin is the one research growth-hormone secretagogue with a proper "after" on record. Its licensed analogue, EGRIFTA, went through two placebo-controlled phase 3 trials totalling 806 patients, a 52-week extension in which some patients were quietly switched to placebo, and a decade of follow-on studies in obese adults without HIV. That means the question "what does tesamorelin before and after actually look like" can be answered with CT scans, waist tapes and blood panels rather than with somebody's bathroom mirror.

This page does not carry photos or testimonials. It sets out what the published data say happens week by week, what a researcher should record before starting so that the "after" means something, how big the realistic change is, what is noise, and what disappears when the compound is stopped. The Bureau's tesamorelin guide covers the pharmacology; this page is only about the timeline.

Where the before-and-after data come from

Four bodies of evidence do most of the work here. First, the 12-week dose-ranging study (61 HIV-positive patients with abdominal fat accumulation, 1 mg or 2 mg daily against placebo), which is the earliest fixed timepoint in the literature. Second, the two 26-week phase 3 trials, pooled as 543 patients on 2 mg tesamorelin against 263 on placebo, with a 26-week extension in which responders were re-randomised to keep going or to switch to placebo. Third, a 12-month trial of 60 abdominally obese adults without HIV, which shows the effect is not specific to antiretroviral lipodystrophy. Fourth, a six-month trial of 50 patients that added liver-fat imaging and, usefully, a two-week glucose check.

Two caveats before the numbers. Every trial measured visceral adipose tissue (VAT) by CT at the L4 to L5 level, in square centimetres of cross-sectional area, not by tape or scale. And the trial population was mostly men in their forties with a specific pattern of central fat; the size of the effect in a lean researcher with a normal GH axis is not established anywhere.

The week-by-week timeline

Read the last row carefully. The VAT curve is not linear for a year. The pooled analysis shows most of the visceral loss is in by week 26 and the second 26 weeks add a few percentage points. Anyone expecting the six-month result to double by twelve months is expecting something the trials did not find.

What to record before the first dose

The trials used CT scans. Most researchers will not. That makes the baseline log more important, not less, because the effect is specifically visceral and the ordinary measures (scale, mirror) are poor at seeing visceral change. The Bureau suggests the following minimum, recorded on the same day of the week, in the morning, fasted.

• Waist circumference at the navel, same tape, same tension, three readings averaged. This is the one cheap measurement that tracked VAT in the trials (a 2 cm placebo-adjusted change at 26 weeks).
• Scale weight as a 7-day rolling average, because tesamorelin barely moves total weight (trunk fat -1.0 kg over 26 weeks) and a single reading is dominated by water.
• Fasting glucose and HbA1c. The label records an HbA1c of 6.5% or above in 4.5% of tesamorelin patients versus 1.3% on placebo at 26 weeks, and a hazard ratio of 3.3 for developing diabetes. If you do not know your starting glucose, you cannot see the signal.
• IGF-1, because 47.4% of patients on 26 weeks of treatment had IGF-1 more than 2 standard deviations above normal and 35.6% were above 3. The label says to consider stopping when it stays elevated. A baseline value is the only way to interpret a follow-up.
• Fasting triglycerides and the cholesterol to HDL ratio, which moved in every trial and are more sensitive than the tape.
• Front and side photographs in the same room, same light, same lens distance, same time of day, weekly. Note that subcutaneous fat did not change in any trial, so the photographs may look unremarkable even when the CT would not.
• A symptom log for joint pain, hand tingling, ankle swelling and injection-site reactions, which are the side effects that decided most discontinuations.

If you are also running a DEXA or a CT, book the baseline scan before the first dose rather than in week two; the fluid shift in the first fortnight can distort lean-mass readings.

Realistic magnitude, and what is noise

The trial effect is a 15% to 18% reduction in visceral fat area at 26 weeks. In absolute terms that was 21 to 27 cm² in the phase 3 studies and 34 cm² in the six-month liver-fat trial. It is a real change and it showed up in liver enzymes, triglycerides and carotid intima-media thickness in the follow-on studies. It is not a transformation. The people in these trials lost about a kilo of trunk fat, 2 to 3 cm of waist and essentially no scale weight.

Noise, by contrast, is large relative to that. Day-to-day waist variation from food and water is routinely 1 to 2 cm, the same size as the 26-week placebo-adjusted effect. Scale weight varies by 1 to 2 kg over a week. The 12-week VAT change, although -15.7% on 2 mg, was not statistically distinguishable from placebo with 61 people, which tells you how wide the individual spread is. And the placebo groups themselves moved: -1 cm of waist and, in one study, -2% VAT, presumably from being weighed and watched. A researcher with no control arm is comparing against their own memory.

The IGF-1 response is the one place the magnitude is large: an 81% rise at 26 weeks in the NEJM trial, a mean increase of 108 ng/mL in the pooled analysis. That number is why the label asks for monitoring.

What reverses on stopping

This is the clearest part of the tesamorelin record, and the part most before-and-after pages leave out. In the 52-week extension, patients who had responded at week 26 were re-randomised. Those kept on tesamorelin held their result (+3 cm² and -11 cm² in the two studies over the second 26 weeks). Those switched to placebo regained +25 cm² and +24 cm², which is essentially the whole 26-week loss, in the same 26 weeks it took to lose it. The 2008 paper's summary is three words: "VAT reaccumulated". Triglycerides followed the fat back up.

The pharmacology explains it. Tesamorelin is a GHRH analogue; it raises endogenous GH pulses while it is present and does nothing structural to the adipocyte. Remove the stimulus and the visceral depot refills at roughly the rate it emptied. There is no published evidence of a lasting reset, and the licensed product is prescribed as continuous therapy for exactly that reason. The Bureau's peptide cycles page discusses how researchers handle compounds whose effect is entirely on-treatment.

Where people misattribute results

Scale weight as fat loss. Tesamorelin does not move the scale much; if the scale drops several kilos, something else (diet, a GLP compound, illness) did it. If the scale rises in weeks 2 to 4, that is more likely the fluid retention on the label than muscle.

A softer or flatter stomach as "the tesamorelin working". Subcutaneous abdominal fat, the layer you can pinch, did not change in any trial (-2 cm² versus +2 cm² in the pooled data). Visceral fat sits behind the abdominal wall. A pinch test measures the wrong depot.

Stack effects. Tesamorelin is routinely paired with ipamorelin or CJC-1295 in research protocols. If the "after" came from a stack, the trial numbers on this page no longer apply, and the extra GH pulse from a GHRP will add its own water and appetite effects. See the tesamorelin and ipamorelin stack page for what is and is not known about the combination.

Population. The headline numbers come from HIV-positive patients with lipodystrophy and from obese adults with blunted GH secretion. In both, the GH axis was suppressed before treatment. The 12-month trial in obese non-HIV adults found a smaller absolute VAT change (-16 cm² versus +19 cm² on placebo) than the lipodystrophy trials. A younger researcher with a normal IGF-1 is starting from a different baseline and should expect less, not more.

Lipids and liver enzymes as proof of fat loss. These improved in the trials, but they also respond to diet within days. A triglyceride drop in week 2 is not visceral fat; it is last week's meals.

Joint pain as "growth". Arthralgia occurred in 13.3% of treated patients versus 11.0% on placebo. It is a GH-related fluid effect, not a sign that anything is being rebuilt.

Sourcing and dosing notes

The trials used 2 mg once daily; the current EGRIFTA SV label uses 1.4 mg of a more concentrated formulation. Research protocols generally mirror the 1 to 2 mg range, and the tesamorelin dosage guide walks through the reconstitution arithmetic. To convert a vial size and bacteriostatic water volume into syringe units, use the tesamorelin dosage calculator.

On sourcing: tesamorelin is a peptide that degrades if handled badly, and the trial-sized effect depends on a full daily dose for six months, so a vendor with per-batch lab results matters more than a few dollars per vial. The Bureau's top-scored source for tesamorelin at the time of writing is Pantheon Peptides, which links a lab results page from each product listing and ships from the US. Check price at Pantheon Peptides The Pantheon Peptides review sets out how the scorecard treats it, and best peptides for fat loss puts tesamorelin next to the GLP class for anyone whose goal is scale weight rather than visceral area.

Tesamorelin is a research compound. The numbers above describe licensed-drug trials in specific patient populations; nothing here is medical advice, and the Bureau does not advise anyone on using research compounds.

Frequently Asked Questions

How long does tesamorelin take to show results?

In the trial data, IGF-1 rises within the first two weeks, but fat change is not measurable until later. The earliest fixed timepoint in the literature is 12 weeks, where the 2 mg group showed trunk fat down 9.2% by DEXA and visceral fat down 15.7% by CT, the latter not statistically significant in a 61-patient study. The fair before-and-after point is 26 weeks, where visceral fat fell 15% to 18% against placebo in the phase 3 trials. Expect nothing visible in the first month.

How much visceral fat does tesamorelin remove?

Roughly 15% to 18% of visceral adipose tissue area at 26 weeks in the phase 3 trials, which was 21 to 27 cm² by CT, and 17.5% at 52 weeks in patients who stayed on treatment. The 12-month trial in obese adults without HIV found a 35 cm² treatment effect. Subcutaneous abdominal fat did not change in any study. Total body weight barely moved: trunk fat fell about 1 kg over 26 weeks, and waist circumference dropped 2 to 3 cm.

Does tesamorelin fat loss come back after stopping?

Yes, in the only controlled data available. In the 52-week extension, patients who had responded at week 26 and were switched to placebo regained 24 to 25 cm² of visceral fat over the next 26 weeks, essentially the whole loss, while those who continued held their result. Triglycerides reverted too. Tesamorelin raises GH only while it is present and does nothing structural to fat cells, so there is no published evidence of a lasting effect once it is withdrawn.

What should I measure before starting tesamorelin?

At minimum: waist circumference at the navel averaged over three readings, a seven-day rolling scale weight, fasting glucose and HbA1c, IGF-1, fasting triglycerides, and standardised photographs in the same light. The glucose and IGF-1 baselines matter most, because the label reports IGF-1 above 2 standard deviations in 47% of treated patients and an increased rate of HbA1c reaching 6.5%. If you plan a DEXA or CT, book the baseline before the first dose rather than in week two, when fluid shifts can distort the reading.

Why has my weight gone up on tesamorelin?

The most likely explanation in the first month is fluid. The EGRIFTA label lists fluid retention as a known effect of stimulating GH, with peripheral oedema in 6.1% of patients, arthralgia in 13.3% and paraesthesia in 4.8%. The trials found no meaningful change in total body weight over 26 weeks; trunk fat fell by about 1 kg while other compartments were stable. A scale gain of half a kilo to a kilo in weeks two to four is consistent with the trial data and is not muscle.

Is tesamorelin worth it for someone who is already lean?

The published evidence cannot answer that. Every trial enrolled people with excess abdominal fat and a suppressed GH axis, either from antiretroviral lipodystrophy or from obesity with reduced GH secretion. The 12-month study in obese non-HIV adults found a smaller absolute visceral change than the lipodystrophy trials, which suggests the effect scales with how much visceral fat and how little GH you start with. A lean researcher with a normal IGF-1 is outside the data and should expect less.

Research use only. The compounds discussed are sold as research chemicals and are not approved for human use. Nothing here is medical advice.